- Home
- IBTA vs BEAM Comparison
IBTA vs BEAM Comparison
Compare IBTA & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- BEAM
- Stock Information
- Founded
- IBTA 2011
- BEAM 2017
- Country
- IBTA United States
- BEAM United States
- Employees
- IBTA N/A
- BEAM N/A
- Industry
- IBTA
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IBTA
- BEAM Health Care
- Exchange
- IBTA Nasdaq
- BEAM Nasdaq
- Market Cap
- IBTA 2.2B
- BEAM 1.9B
- IPO Year
- IBTA 2024
- BEAM 2020
- Fundamental
- Price
- IBTA $67.99
- BEAM $28.70
- Analyst Decision
- IBTA Strong Buy
- BEAM Buy
- Analyst Count
- IBTA 9
- BEAM 10
- Target Price
- IBTA $89.67
- BEAM $47.67
- AVG Volume (30 Days)
- IBTA 369.1K
- BEAM 1.0M
- Earning Date
- IBTA 11-13-2024
- BEAM 11-05-2024
- Dividend Yield
- IBTA N/A
- BEAM N/A
- EPS Growth
- IBTA N/A
- BEAM N/A
- EPS
- IBTA 0.48
- BEAM N/A
- Revenue
- IBTA $368,548,000.00
- BEAM $349,643,000.00
- Revenue This Year
- IBTA $18.80
- BEAM N/A
- Revenue Next Year
- IBTA $16.65
- BEAM $10.82
- P/E Ratio
- IBTA $150.85
- BEAM N/A
- Revenue Growth
- IBTA 74.91
- BEAM 328.73
- 52 Week Low
- IBTA $41.87
- BEAM $20.84
- 52 Week High
- IBTA $110.95
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- IBTA N/A
- BEAM 56.65
- Support Level
- IBTA N/A
- BEAM $27.02
- Resistance Level
- IBTA N/A
- BEAM $29.53
- Average True Range (ATR)
- IBTA 0.00
- BEAM 1.73
- MACD
- IBTA 0.00
- BEAM 0.10
- Stochastic Oscillator
- IBTA 0.00
- BEAM 59.63
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.